Remicade Indications/Uses

Remicade is indicated for: Rheumatoid arthritis: Remicade is a "Disease-Controlling Anti-Rheumatic Therapy" (DCART) indicated for: the reduction of signs and symptoms; prevention of structural joint damage (erosions and joint space narrowing); improvement in physical function in patients with active disease despite treatment with methotrexate (MTX), and patients with active disease not previously treated with MTX.
Ankylosing spondylitis: Remicade is indicated for: reduction of signs and symptoms; improvement in physical function; improvement in quality life in patients with active disease.
Psoriatic arthritis: Remicade is indicated for: the reduction of signs and symptoms of arthritis; improvement in physical function; reduction in psoriasis as measured by PASI (an index which combines symptom evaluation and body surface area) in patients with active psoriatic arthritis.
Psoriasis: Remicade is indicated for treatment of moderate to severe plague psioriasis in adults who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA.
Crohn's disease: Remicade is indicated for treatment of moderate to severe Crohn's disease for: reduction of signs and symptoms; induction and maintenance of clinical remission; induction of mucosal healing; improvement in quality of life in patients who have an inadequate response to conventional therapies. Remicade therapy enables patients to reduce or eliminate corticosteroid use.
Paediatric Crohn's disease: Remicade is indicated for the treatment of severe, active Crohn's disease, in paediatric patients aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies. Remicade has been studied only in combination with conventional immunosuppressive therapy.
Fistulizing Crohn's disease: Remicade is indicated for: reduction in the number of draining enterocutaneous and rectovaginal fistulae and maintenance of fistula closure; reduction of signs and symptoms in patients with fistulizing Crohn's disease.
Ulcerative colitis: Remicade is indicated for: reducing signs and symptoms; inducing and maintaining clinical remission; inducing mucosal healing; eliminating corticosteroids used in patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.
Paediatric ulcerative colitis: Remicade is indicated for treatment of severely active ulcerative colitis, in children and adolescents aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6-MP or AZA, or who are intolerant to or have medical contraindications for such therapies.